Clinical Activity and Safety of Pegylated Human IL-10 (AM0010) in Combination With Anti-Pd1.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2016.34.15_suppl.3018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Anti-Tumor Activity of PEGylated Human IL-10 (AM0010) in Patients With Pancreatic or Colorectal Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination With Anti-Pd1 and Anti-Cd137 Immunostimulatory Monoclonal Antibodies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Combination of IL-10 and IL-2 Induces Oligoclonal Human CD4 T Cell Expansion During Xenogeneic and Allogeneic GVHD in Humanized Mice

Heliyon
Multidisciplinary
2017English

Decreased Indoleamine 2,3-Dioxygenase Activity and IL-10/IL-17A Ratio in Patients With COPD

Thorax
PulmonaryRespiratory Medicine
2012English

Combination Treatment With Hypofractionated Radiotherapy Plus IL-2/anti-IL-2 Complexes and Its Theranostic Evaluation

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination With Chemotherapy in Asian Patients With Advanced Solid Tumors: Phase Ib Study

Targeted Oncology
Cancer ResearchOncologyPharmacology
2020English

Induction of Human IL-10-producing Neutrophils by LPS-stimulated Treg Cells and IL-10

Mucosal Immunology
AllergyImmunology
2015English

Response to Anti-Pd1 Therapy With Nivolumab in Metastatic Sarcomas

Clinical Sarcoma Research
Oncology
2016English

Elevated Levels of Anti Inflammatory IL-10 and Pro Inflammatory IL-17 in Malignant Pleural Effusions

Journal of Cardiothoracic Surgery
CardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy